List view / Grid view
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon's biologics license application for MYL-1401H, a proposed biosimilar to Neulasta...
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
12 January 2017 | By Niamh Marriott, Digital Editor
This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast cancers...
10 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Mabion signed a long-term development and commercialisation agreement with Mylan Ireland a wholly owned subsidiary of Mylan N.V.
9 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Mylan and Biocon have submitted a biologics license application for MYL-1401O, a proposed biosimilar trastuzumab, to the FDA through the 351(K) pathway...
25 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Mylan and Biocon, who co-developed this proposed biosimilar, anticipate that this may be the first MAA for a trastuzumab biosimilar accepted by the EMA...
14 September 2015 | By Victoria White
The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study...
14 September 2015 | By Victoria White
Under the terms of the offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share...
28 August 2015 | By Victoria White
Mylan's proposed acquisition of Perrigo received the approval of two-thirds of the votes cast by Mylan shareholders at an extraordinary general meeting...
17 August 2015 | By Victoria White
The ISS has recommended that Mylan shareholders vote "against" the unsolicited offer to acquire all of the outstanding shares of Perrigo...
28 July 2015 | By Victoria White
Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan...
15 July 2015 | By Victoria White
Both Mylan and Dr. Reddy's have launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, which is the generic version of Namenda Tablets, in the US...
8 June 2015 | By Victoria White
Mylan has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide Evohaler under the brand name Sirdupla in the UK...
6 May 2015 | By Victoria White
Teva has acquired Auspex Pharmaceuticals through the successful tender offer for all of the outstanding Auspex shares at $101.00 per share...
28 April 2015 | By Victoria White
Mylan has announced that its Board of Directors has unanimously rejected the unsolicited expression of interest from Teva to acquire the Company...
